[1] |
ZHANG Zan, ZHANG Hui, HE Songhua, LUO Yi.
Four exogenously-polluted components in Tianwang Buxin pills analyzed via TLC and UPLC-QQQ-MS
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 156-162.
|
[2] |
JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling.
Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
|
[3] |
LIU Qian, HU Jing, LI Bo, YANG Xiaojing.
Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
|
[4] |
YIN Yuling, HU Chujuan, ZHANG Xiaomeng, WANG Yu, ZHANG Bing, LIN Zhijian.
Mining and validation of anti-adriamycin cardiotoxic effect of chicory extract
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 858-865.
|
[5] |
HE Xiong, MA Junlong, YANG Guoping.
Adverse events caused by HER2 conjugated antibodies via FAERS
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 915-920.
|
[6] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[7] |
.
Annual report of national adverse drug reaction monitoring (2022)
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
|
[8] |
HUANG Wei, WU Ruiqing, SUN Hua, SHI Jiangong, LIU Qian.
Reversal of multidrug resistance in human oral epithelial cancer cells KBV200 by a natural product
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 403-408.
|
[9] |
XIE Jing, GUAN Fei.
One case of spontaneous hemorrhage of iliopsoas and gluteal muscles induced by drugss
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1299-1302.
|
[10] |
ZHUANG Hongyan, ZANG Yannan, LIU Shanshan, NIU Mengxi, FANG Meng, YIN Dongqing, GUO Wei.
Analysis of neuropsychiatric adverse reactions caused by zolpidem
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 889-892.
|
[11] |
YANG Jia, LI Gen, JIANG Yongxian, TAO Wanjun, CHEN Wenwen, LIANG Hua.
Infant ankle edema and lactic acid increase induced by diazoxide: a case study
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 789-791.
|
[12] |
CUI Xiangli, ZHANG Zhiqi, SUN Liying, GUO Mingxing, ZENG Zhigui, XU Wanyi.
Leflunomide-induced hepatotoxicity: data analysis based on the FDA adverse event reporting system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 426-431.
|
[13] |
WANG Yi, REN Jingtian.
Evaluation and significance of benefit-risk analysis of benzbromarone-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 189-192.
|
[14] |
MENG Dehui, WANG Weilan.
One case of primary adrenal insufficiency induced by pembrolizumab
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 107-110.
|
[15] |
YU Hongli, PANG Yu, SHAO Bo, XIAO Aili, YU Dongmei.
Current Adverse Drug Reaction Reporting and Monitoring of Essential Medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 766-768.
|